The registry aims to collect and analyse information on the antineoplastic treatment of patients with metastatic esophageal, gastric or gastroesophageal junction cancer, treated in palliative intention in daily routine practice in Germany.
Histologically proven stage IV (metastatic) ESCC, EAC, GAC or GEJAC
Planned palliative systemic first-line therapy
Age >= 18 years
Signed informed consent (IC)
No systemic therapy for ESCC, EAC, GAC or GEJAC
Adult patients with metastatic (stage IV) esophageal squamous cell carcinoma (ESCC), esophageal adenocarcinoma (EAC), gastric adenocarcinoma (GAC) or gastroesophageal junction adenocarcinoma (GEJAC), requiring palliative systemic first-line therapy.
Cohort
Prospective
Routine care as per site standard
Other interventionPhysician's choice according to patient's needs. Routine care as per site standard.
Course of treatment (treatment reality)
Documentation of anamnestic data and therapy sequences
Map coordinates are unavailable for these locations. Locations are shown below instead.
GermanyClick on the lead sponsor to view all of their trials.
